Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 24c
November 3, 2022 8:15 AM EDTIntra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.57), $0.24 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $71.9 million versus the consensus estimate of $65.88 million.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
... More